CenterBook Partners LP Sells 245,797 Shares of Pfizer Inc. (NYSE:PFE)

CenterBook Partners LP trimmed its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 79.9% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 61,997 shares of the biopharmaceutical company's stock after selling 245,797 shares during the period. CenterBook Partners LP's holdings in Pfizer were worth $1,645,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Norges Bank acquired a new position in shares of Pfizer during the fourth quarter worth approximately $2,328,986,000. Charles Schwab Investment Management Inc. raised its stake in Pfizer by 19.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock valued at $4,124,330,000 after purchasing an additional 25,315,159 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in Pfizer in the 4th quarter worth $274,694,000. Massachusetts Financial Services Co. MA increased its holdings in shares of Pfizer by 7.5% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company's stock worth $2,029,604,000 after purchasing an additional 5,350,381 shares during the period. Finally, APG Asset Management N.V. raised its position in shares of Pfizer by 1,106.0% during the fourth quarter. APG Asset Management N.V. now owns 5,619,213 shares of the biopharmaceutical company's stock valued at $143,967,000 after buying an additional 5,153,257 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Remove Ads

Insiders Place Their Bets

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The shares were bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now owns 27,707 shares of the company's stock, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 0.06% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have commented on PFE. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Truist Financial decreased their price target on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday, December 18th. The Goldman Sachs Group restated a "neutral" rating and issued a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Citigroup reiterated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Finally, UBS Group decreased their price objective on Pfizer from $28.00 to $24.00 and set a "neutral" rating on the stock in a report on Tuesday, April 8th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $31.07.

Pfizer Price Performance

NYSE:PFE traded up $0.27 during mid-day trading on Monday, reaching $22.18. 45,818,399 shares of the company were exchanged, compared to its average volume of 40,264,702. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The stock has a market cap of $125.79 billion, a PE ratio of 15.73, a PEG ratio of 0.64 and a beta of 0.67. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The company has a fifty day moving average of $25.25 and a 200 day moving average of $26.38.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. During the same period last year, the firm earned $0.10 EPS. The business's revenue for the quarter was up 24.7% on a year-over-year basis. On average, research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.